Clinical trials: Normal Population
Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who…
- Trial name
- NCT06915766
- Testing
- Bezuclastinib
- Where
- 23 sites in United States
- Sponsor
- Cogent Biosciences, Inc.
Androgenetic Alopecia (AGA), Androgenetic Alopecia
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that…
- Conditions
- Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
- Trial name
- NCT07146022
- Testing
- VDPHL01 QD, VDPHL01 BID
- Where
- 71 sites in United States
- Volunteers
- 552 people
- Sponsor
- Veradermics, Inc.
Breast Cancer, Leukemia, Myeloid, Chronic
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
The purpose of this study is to assess the pharmacokinetics of bosutinib and the safety and tolerability of bosutinib in healthy subjects and subjects with liver disease.
- Trial name
- NCT00759837
- Testing
- Bosutinib
- Where
- Poland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Primary Sjögren's Syndrome
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)
- Trial name
- NCT02291029
- Testing
- CFZ533 active - Cohort 1, CFZ533 active - Cohort 2, CFZ533 active -Cohort 3
- Where
- 9 sites in United States, Germany and 3 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Rheumatoid
Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)
Safety, pharmacokinetics, pharmacodynamics [CD11b/CD18 (Mac-1) expression] and efficacy.
- Trial name
- NCT02247375
- Testing
- Low dose of BIIL 284 BS tablets, High dose of BIIL 284 BS tablets
- Volunteers
- 26 people
- Sponsor
- Boehringer Ingelheim
Acne
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe…
- Trial name
- NCT02965456
- Testing
- IDP 121 Lotion, IDP-121 Vehicle Lotion
- Where
- 34 sites in United States
- Volunteers
- 820 people
- Sponsor
- Bausch Health Americas, Inc.
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Androgenetic Alopecia
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
The goal of this clinical trial is to assess the safety of the AH-001 drug substance at concentrations of 0.2%, 0.5%, 1%, and 2% in healthy volunteers and male subjects with androgenetic alopecia (AGA).
- Trial name
- NCT06927960
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Rosacea
Rosacea Prevalence in General Population - Pilot Study
The purpose of this study is to test and refine, a subject questionnaire aimed to be used in a general population rosacea prevalence study.
- Trial name
- NCT02292836
- Testing
- Questionnaire testing
- Where
- 2 sites in Canada, Sweden
- Volunteers
- 120 people
- Sponsor
- Galderma R&D
Tinea Pedis
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.
- Trial name
- NCT04883593
- Testing
- TA103
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Lupus Erythematosus, Systemic
A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy of ustekinumab in Chinese participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard-of-care treatments.
- Trial name
- NCT04060888
- Testing
- Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 milligram (mg)
- Sponsor
- Janssen Research & Development, LLC
Neurodermatitis
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Primary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapy or when those therapies are not advisable.
- Trial name
- NCT04202679
- Testing
- Dupilumab SAR231893, Moisturizers, Low to medium potent topical corticosteroids
- Where
- 57 sites in United States, Canada and 9 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Acne Vulgaris
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.
- Trial name
- NCT03650361
- Testing
- Adapalene Gel 0.3%, Differin 0.3% Topical Gel
- Where
- 10 sites in United States, Belize
- Volunteers
- 755 people
- Sponsor
- Aleor Dermaceuticals Limited
Leiomyomas
Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma
The purpose of this study is to determine whether ulipristal acetate is effective in the treatment of females with anemia associated with uterine leiomyomas. The safety of this product will also be evaluated.
- Trial name
- NCT01553123
- Testing
- Ulipristal Acetate, Iron
- Where
- 47 sites in United States
- Sponsor
- Watson Pharmaceuticals
Atopic Dermatitis
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
This is a Phase 2b study to determine the safety, tolerability, pharmacokinetic (PK), and efficacy of ATI-1777 in patients 12 to 65 years old with mild to severe Atopic Dermatitis.
- Trial name
- NCT05432596
- Testing
- ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w
- Where
- 32 sites in United States
- Volunteers
- 250 people
- Sponsor
- Aclaris Therapeutics, Inc.
Lichen Simplex Chronicus
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged…
- Trial name
- NCT06687980
- Testing
- Dupilumab
- Where
- 63 sites in United States, Argentina and 15 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Arthritis, Rheumatoid
A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy
The purpose of this study is to evaluate the efficacy of ustekinumab and CNTO 1959 in reducing the signs and symptoms of disease in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy and…
- Trial name
- NCT01645280
- Testing
- Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4)
- Where
- 47 sites in United States, Argentina and 9 more
- Volunteers
- 274 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Rheumatoid
A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
This is a randomized, double-blind, parallel group, multicenter clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of LBEC0101 compared to Enbrel in subjects with active Rheumatoid Arthritis…
- Trial name
- NCT02357069
- Testing
- Enbrel, LBEC0101
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 372 people
- Sponsor
- LG Life Sciences
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
- Trial name
- NCT07160608
- Testing
- Tarperprumig
- Where
- 78 sites in Argentina, Australia and 12 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Rheumatoid Arthritis
BTT-1023 in Rheumatoid Arthritis
Patients with adult-onset rheumatoid arthritis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo.
- Trial name
- NCT00851240
- Testing
- BTT-1023
- Where
- Bulgaria
- Volunteers
- 24 people
- Sponsor
- Biotie Therapies Corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.